Shaheen Ihab Sakr, Harvey Ben, Watson Alan R, Pandya Hitesh C, Mayer Anton, Thomas David
Children & Young People's Kidney Unit, Nottingham City Hospital, NHS Trust, Nottingham, UK.
Pediatr Crit Care Med. 2007 Jul;8(4):362-5. doi: 10.1097/01.PCC.0000269378.76179.A0.
We report the frequency of usage, patient demographics, and outcomes in children treated with continuous venovenous hemofiltration (CVVH) in three pediatric intensive care units (PICUs), with one unit providing combined extracorporeal membrane oxygenation (ECMO) and CVVH.
Prospective database analysis.
Three regional PICUs in the Trent Haemofiltration Network with two general PICUs admitting 450-500 patients annually and the other providing regional cardiac support and a supraregional service for ECMO (600-650 admissions annually with 50 ECMO patients).
Children who underwent CVVH alone or in combination with ECMO or other therapies between January 2000 and December 2002.
None.
There were 115 children (58 male) treated, with a median age of 18 months (range 1 day to 17 yrs) and median weight of 12 kg (range 1.8-119 kg). In the two PICUs without ECMO, CVVH was undertaken in 2.5% of admissions annually compared with 3% of annual admissions to the PICU with an ECMO service. Fifty-five patients received CVVH alone (group 1), while 53 patients underwent CVVH in conjunction with ECMO (group 2). In addition, five patients received plasmafiltration followed by CVVH, and two patients were treated with combined CVVH and molecular adsorbents recirculating system. Mean duration of therapy in group 1 was 142 hrs (1-840 hrs) and in group 2,231 hrs (3-1104 hrs). Overall patient survival was 43% with 29 of 55 (53%) CVVH patients surviving and 18 of 53 (34%) of those treated with ECMO plus CVVH.
Performing CVVH in a heterogeneous population with large age and weight ranges poses significant clinical and technical challenges. The low frequency of CVVH use, as well as the use of other extracorporeal therapies, also raises problems with maintaining nursing skills. Objective clinical and biochemical markers for commencing CVVH alone or in combination with ECMO remain to be defined.
我们报告了在三个儿科重症监护病房(PICU)中接受持续静静脉血液滤过(CVVH)治疗的儿童的使用频率、患者人口统计学特征及治疗结果,其中一个病房同时提供体外膜肺氧合(ECMO)和CVVH治疗。
前瞻性数据库分析。
特伦特血液滤过网络中的三个地区性PICU,其中两个普通PICU每年收治450 - 500名患者,另一个提供区域性心脏支持及ECMO的超区域服务(每年收治600 - 650名患者,其中50名接受ECMO治疗)。
2000年1月至2002年12月期间单独接受CVVH治疗或联合ECMO或其他治疗的儿童。
无。
共治疗115名儿童(58名男性),中位年龄18个月(范围1天至17岁),中位体重12千克(范围1.8 - 119千克)。在两个不提供ECMO的PICU中,每年CVVH治疗的患者占入院患者的2.5%,而在提供ECMO服务的PICU中这一比例为3%。55名患者单独接受CVVH治疗(第1组),53名患者接受CVVH联合ECMO治疗(第2组)。此外,5名患者先接受血浆滤过再进行CVVH治疗,2名患者接受CVVH联合分子吸附再循环系统治疗。第1组的平均治疗时长为142小时(1 - 840小时),第2组为231小时(3 - 1104小时)。总体患者生存率为43%,55名接受CVVH治疗的患者中有29名(53%)存活,53名接受ECMO联合CVVH治疗的患者中有18名(34%)存活。
在年龄和体重范围差异较大的异质性人群中进行CVVH治疗面临重大的临床和技术挑战。CVVH的低使用频率以及其他体外治疗方法的应用,也给维持护理技能带来了问题。单独开始CVVH治疗或联合ECMO治疗的客观临床和生化标志物仍有待确定。